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Skeletal muscle development in the vertebrate embryo critically depends on the myogenic regulatory factors (MRFs) including MRF4 and
Myf5. Both genes exhibit distinct expression patterns during mouse embryogenesis, although they are genetically closely linked with
multiple regulatory elements dispersed throughout the common gene locus. MRF4 has a biphasic expression profile, first in somites and later
in foetal skeletal muscles. Here, we demonstrate by transgenic analysis that elements within a 7.5-kb promoter fragment of the MRF4 gene
are sufficient to drive the embryonic wave of expression very similar to the endogenous gene in somites of mouse embryos. In contrast, a 3-
kb fragment of the proximal promoter fails to support expression in the myotome, suggesting that essential cis-acting elements are located
between 7.5 and 3 kb upstream of MRF4. Further analysis of this sequence delimits an essential region between 6.6 and 5.6 kb that
together with the 3-kb promoter fragment directs transgene expression in the epaxial myotome of all somites during the appropriate
developmental period. These data provide evidence that the partly overlapping expression patterns of Mrf4 and Myf5 in somites are
controlled by distinct regulatory elements. We also show that 11.4 kb sequence upstream of MRF4, including the promoter and the somitic
control region identified in this study, is not sufficient to elicit target specificity towards the strong Myf5 (58/48 kb) enhancer, suggesting
that additional yet unidentified elements are necessary to convey promoter selectivity and protect the MRF4 gene from this enhancer.
D 2004 Elsevier Inc. All rights reserved.Keywords: MRF4; Myf5; Gene regulation; Myogenic regulatory factors; Cis-acting control elements
Introduction function as muscle determination genes driving cells into theDevelopment of skeletal muscles in the vertebrate embryo
depends on and is coordinated by the myogenic regulatory
factors (MRFs), Myf5 (Braun et al., 1989), myogenin
(Edmondson and Olson, 1989; Wright et al., 1989), MRF4
(Braun et al., 1990; Miner and Wold, 1990; Rhodes and
Konieczny, 1989), and MyoD (Davis et al., 1987). These
proteins belong to the family of basic helix-loop-helix
transcription factors that control determination of the myo-
genic cell lineage and differentiation of myoblasts in all
muscle-forming regions of the embryo. Targeted gene dis-
ruptions of individual MRFs and combined mutations have
led to the conclusion that Myf5 and MyoD independently0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: h.arnold@tu-bs.de (H.-H. Arnold).skeletal muscle program (Braun et al., 1992; Rudnicki et al.,
1992; Tajbakhsh et al., 1996). In mouse mutants deficient for
both Myf5 and MyoD, muscle precursor cells are absent and
skeletal muscle fails to form (Rudnicki et al., 1993). In line
with a determining role in myogenesis, Myf5 and MyoD are
capable of remodeling chromatin of muscle-specific genes to
allow their transcriptional activation (Bergstrom and Taps-
cott, 2001; Gerber et al., 1997). Myogenin functions as
muscle differentiation factor during embryogenesis, since
in its absence many muscle genes are not activated and
myoblasts fail to fuse (Hasty et al., 1993; Nabeshima et al.,
1993; Venuti et al., 1995). MRF4 may also be involved in
muscle cell differentiation (Black et al., 1995; Naidu et al.,
1995), particularly in the early myotome, the first muscle
formed in the embryo (Buckingham, 1994; Nabeshima et al.,
1993). In MyoD/MRF4 double mutants, most myoblasts do
not differentiate properly suggesting that MyoD is also
implicated in differentiation and myogenin apparently is
unable to functionally substitute for both factors (Rawls et
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clear, as all available mutant alleles also affect Myf5 expres-
sion or lead to up-regulation of myogenin (Braun and
Arnold, 1995; Olson et al., 1996; Patapoutian et al., 1995;
Yoon et al., 1997; Zhang et al., 1995).
Both, the emergence of muscle cell precursors as well as
their subsequent differentiation in the embryo are dependent
on signals, presumably from adjacent tissues, that activate
the expression of the aforementioned muscle regulatory
genes. In vertebrates, skeletal muscles of trunk, limbs,
tongue, and diaphragm are derived from somites, whereas
facial muscles arise from paraxial head and prechordal plate
mesoderm (Christ and Wilting, 1992; Noden, 1983; Noden
et al., 1999). Myf5 is the first member of the MRF family to
be expressed in somites following their rostrocaudal se-
quence of development. Expression begins in the epaxial
(dorsomedial) dermomyotome at E8.0 and slightly later in
the hypaxial (ventrolateral) dermomyotome marking muscle
progenitor cells in both regions that will form the myotome
(Ott et al., 1991; Tajbakhsh et al., 1997). The hypaxial
domain that develops into the somitic bud constitutes the
source for progenitors of intercostal and body wall muscles,
while cells of the epaxial domain will form deep back
muscles (Christ et al., 1983). At limb level, the hypaxial
dermomyotome harbors migratory muscle precursors that do
not express MRFs until they have entered the limb buds and
start the myogenic program by accumulating Myf5 and
MyoD almost simultaneously (Christ and Brand-Saberi,
2002). Expression of myogenin and MRF4 in somites
follows the onset of Myf5 with a delay of 0.5 and 1 day,
respectively, while MyoD expression starts approximately
2.5 days after Myf5 (Bober et al., 1991; Sassoon et al.,
1989). In branchial arches, cells that are derived from
anterior paraxial mesoderm and subsequently contribute to
facial muscles also express Myf5 first but never activate the
MRF4 gene (Bober et al., 1991; Hinterberger et al., 1991).
Thus, Myf5 identifies muscle precursors and is the first of
the MRF genes expressed at all sites where myogenesis
commences in the embryo. Genetic evidence argues that
expression of MyoD requires either Myf5 or Pax3, placing
both genes upstream of MyoD (Tajbakhsh et al., 1997).
Embryonic expression of the myogenin gene also appears to
depend on Myf5 (Braun et al., 1992), and an essential E-box
binding site has been identified in the myogenin promoter
by transgenic analysis (Cheng et al., 1993; Yee and Rigby,
1993). Critical transcription factors for embryonic MRF4
expression in vivo have not been defined yet.
Significantly, each of the four myogenic basic helix-loop-
helix transcription factors when overexpressed in a variety of
nonmuscle cells can convert these cells to the muscle
phenotype, suggesting that the individual MRFs have similar
biochemical properties and intrinsic biological functions.
Indeed, targeted insertion of the MRF4 coding region into
the myogenin locus restores myoblast fusion in the embryo
indicating that MRF4 protein can compensate for the loss of
myogenin, if expressed at the correct developmental timeand location (Zhu and Miller, 1997). Thus, the apparently
distinct roles of MRFs in myogenesis observed with the
individual mouse null mutants are likely to be, at least in
part, due to their different spatial and temporal expression
patterns (Arnold and Braun, 2000). Knowledge of how these
specific expression patterns are set up and maintained is
therefore crucial for a deeper understanding of the complex
processes associated with vertebrate myogenesis.
Myf5 and MRF4 genes are genetically linked approxi-
mately 7 kb apart in the same transcriptional orientation in
all analyzed vertebrate species, suggesting that their expres-
sion may be coordinately controlled by evolutionary con-
served mechanisms (Braun et al., 1990; Patapoutian et al.,
1993; Saitoh et al., 1993). However, both genes exhibit
different expression profiles with some overlap in somites
where MRF4 is transiently coexpressed with Myf5 between
E9.0 and E12.5 (Bober et al., 1991; Hinterberger et al.,
1991; Summerbell et al., 2002). In contrast to Myf5, which
is considerably down-regulated in foetal skeletal muscle and
essentially absent in postnatal muscle fibers, MRF4 tran-
scripts accumulate during a second wave of expression in
skeletal muscle of foetal stages and persist as the predom-
inant MRF in postnatal musculature. Molecular mechanisms
underlying the complex control of the Myf5/MRF4 gene
locus at the various sites of myogenesis in the embryo are
largely unknown. However, several regulatory regions have
been mapped within 140 kb of genomic DNA using yeast
(YAC) and bacterial artificial chromosomes (BAC) in trans-
genic mice (Carvajal et al., 2001; Hadchouel et al., 2000;
Zweigerdt et al., 1997). Modular enhancer elements that
control different aspects of Myf5 expression in distinct
domains and various muscle precursor populations have
been identified within the intra- and intergenic regions and
at large distance to the genes. The sequence between the
MRF4 and Myf5 gene contains enhancers that specifically
drive Myf5 expression in the early epaxial dermomyotome
and in branchial arches where MRF4 is not expressed
(Patapoutian et al., 1993; Summerbell et al., 2000; Teboul
et al., 2002). The early epaxial enhancer located near the 3V
end of the MRF4 gene appears to mediate sonic hedgehog
signaling that drives the initial and transient expression of
Myf5 in the most dorsal epaxial domain (Borycki et al.,
1999; Gustafsson et al., 2002). Other enhancers within the
Myf5 gene itself and more than 88 kb upstream direct early
expression in the hypaxial dermomyotome (Carvajal et al.,
2001; Summerbell et al., 2000). The sequence between 58
and 48 kb from Myf5 controls expression in limb buds
and somites (Carvajal et al., 2001; Hadchouel et al., 2000;
Zweigerdt et al., 1997). Dissection of this 10-kb sequence
interval revealed elements that promote transgene expres-
sion in cervical somites and limb buds and contribute to the
correct spatial pattern in myotomes as well as to its
maintenance (Buchberger et al., 2003; Hadchouel et al.,
2003). Control elements regulating MRF4 gene expression
are less well characterized. A 6.5-kb sequence immediately
upstream of the mouse MRF4 gene was shown to be
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muscle but failed to promote early transcription in somites
(Patapoutian et al., 1993). The same region exhibited
enhancer activity in cultured myoblasts (Kerkvliet and
Hinterberger, 1997) and fast muscle fibers in the foetus
(Pin and Konieczny, 2002). The 8.5-kb proximal promoter
sequence of the rat MRF4 gene also drives expression in
foetal muscle and in a subset of somites (thoracic only),
suggesting that additional regulatory elements are required
for the entire anterior–posterior axis (Pin et al., 1997). Far
upstream genomic segments have been implicated in the
early hypaxial expression of MRF4 by transgenic analysis
of BAC deletion series (Carvajal et al., 2001). Thus,
multiple regulatory sequences are present and interdigitated
throughout the MRF4-Myf5 locus and it is not clear how
they specifically and differentially control the activity of
either promoter.
Here, we describe the systematic transgenic analysis to
identify element(s) that drive the early pattern of MRF4
expression in somites. We present evidence that a control
region situated between 6.6 and 5.6 kb upstream of the
MRF4 coding sequence is required to recapitulate myotomal
expression in all somites along the A–P axis. We further-
more demonstrate that the MRF4 promoter is responsive to
the 58/48 kb Myf5-specific enhancer when both ele-
ments are juxtaposed in the transgene. This result implies
that enhancer–promoter selection requires additional ele-
ments that normally shield the MRF4 promoter from the
potent upstream enhancer in the genomic context.Materials and methods
Construction of MRF4 transgenes
Two YACs of different length were derived from clone
ICRFy 903B1022, containing the mouse MRF4/Myf5 gene
locus using homologous recombination with B1 repetitive
elements in yeast as reported previously (Zweigerdt et al.,
1997). Insertion of the nlacZ reporter gene into the AUG
start codon of the MRF4 gene was also performed by
homologous recombination as already described for the
Myf5 gene (Zweigerdt et al., 1997). Briefly, the MRF4
targeting vector was constructed by fusing the 217-bp SalI/
KpnI fragment of MRF4 exon 1 in frame to the nlacZ gene
in plasmid pPD-46.21 (Fire et al., 1990). The yeast selection
marker Ura 3 was isolated as BamHI fragment from plasmid
pYDp-U (Berben et al., 1991), linked to the 2.7-kb KpnI/
BamHI fragment from the MRF4 gene, and the combined
fragment was then cloned downstream of nlacZ in the above
vector. For yeast transformation, the entire recombination
cassette was excised from the vector. Upon selection of
recombinant YACs and their characterization by Southern
blot analysis, the MRF4-nlacZ reporter gene including
approximately 20 kb upstream and 15 kb downstream
flanking sequence was recuperated from the recombinantYAC and subcloned into a cosmid vector by standard
recombinant DNA technology (Sambrook et al., 1989).
Individual transgenes were obtained by digestion of the
cosmid with restriction endonucleases, as indicated in Fig.
1. Resulting fragments were subcloned into the NotI site of
the pGEM-T easy vector (Promega). For constructs MRF4-
VII, MRF4-IX, and MRF4-X subfragments were generated
by PCR using proofreading Pfu DNA polymerase (Prom-
ega) and the appropriate primers centered around the indi-
cated restriction sites (Fig. 1). The PCR products were
joined to the PmeI site in plasmid MRF4-V. All cloned
PCR products were sequenced to ascertain the correct
nucleotide sequence.
Production of transgenic mice
Transgenic mice were generated by pronucleus injection
of single-cell embryos from ICR crosses as described (Yee
and Rigby, 1993). pGEM-T easy vector sequence was
removed from all constructs before injections by digestion
with NotI restriction enzyme and separation of fragments on
agarose gels. Fragments carrying the transgenes were iso-
lated by electroelution, purified twice with phenol or chlo-
roform and once with chloroform alone. Recovered DNA
was dissolved in 10 mM Tris–HCl, pH 8.5, run over a
ProbeQuant G-50 column (Amersham Biosciences), repre-
cipitated and washed several times with ethanol. Purified
fragments were dissolved in 0.1 TE buffer made with
sterile water specified for embryo transfer (Sigma). All
constructs were tested in multiple transient transgenic em-
bryos and stable transgenic mouse lines to ascertain statis-
tical significance of the observed expression patterns. Two
to 10 copies of transgenes were integrated in mouse lines,
but no strict correlation to lacZ expression levels was
observed.
Whole-mount staining for b-galactosidase activity and
histological sections
Embryos were collected at various developmental stages
counting the day of transfer as E0.5. Isolated embryos
were fixed in 0.2% glutaraldehyde dissolved in buffer B
(PBS containing 5 mM EGTA and 2 mM MgCl2) for 10–
30 min at room temperature. Fixed embryos were then
washed in three changes of buffer C (buffer B plus 0.01%
sodium desoxycholate and 0.02% Nonidet P-40) for 30
min each and incubated in staining solution (2 mM MgCl2,
5 mM EGTA, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6,
0.01% Nonidet P-40, and 0.1% X-gal dissolved in PBS)
overnight at room temperature. For sections embryos were
embedded in 0.5% gelatin/30% albumin/20% sucrose in
PBS and cut at 40–50 Am using a vibratome (Leica VT
1000S). Pictures of whole-mount embryos were taken
under a Leica MZ 12 stereomicroscope using a Polaroid
3CCD color camera and Polaroid DMC2 software. Sec-
tions were photographed on a Leica DM-RBE microscope
Fig. 1. Expression pattern of YACs carrying the MRF4 reporter gene in chimeric mouse embryos (A) and schematic representation of MRF4 transgenes (B).
Two YACs containing 85 or 36 kb sequence upstream of the mouse MRF4 gene (line drawings not to scale) and the bacterial lacZ gene inserted into the MRF4
open reading frame were used to generate chimeric mouse embryos via ES cells as described previously (Zweigerdt et al., 1997). MRF4-dependent h-
galactosidase activity of the longer (a) and shorter (b) YAC in somites of E10.5/11 embryos is shown. Sections reveal that both constructs are appropriately
expressed in the myotome (c and d). A series of plasmid-based transgenes was constructed using a 35.4-kb fragment as starting material that was recuperated
from the recombinant YAC encompassing the modified MRF4 gene (B). This and successively shorter fragments obtained by digestion with the indicated
restriction enzymes were cloned into the NotI site of pGEM-T easy vector to yield the various transgenes referred to by Roman numerals. Internal deletions of
the promoter fragment (MRF4VII, MRF4-IX, and MRF4-X) were generated by PCR using primers at the indicated restriction sites. Coordinates of the cloned
fragments are given relative to the MRF4 gene counting the first nucleotide of the cDNA as +1. Light and dark blue boxes highlight MRF4 (Myf5) and nlacZ
genes, respectively. The red box marks the Ura gene used as selection marker in yeast.
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with Adobe Photoshop.Results
The 7.5-kb promoter fragment of the MRF4 gene directs
transgene expression in all somites of the mouse embryo
To investigate the spatiotemporal regulation of MRF4
expression, we initially analyzed chimeric mice carrying the
MRF4/Myf5 locus on yeast artificial chromosomes (YACs)
of approximately 600 kb length, as previously described for
the Myf5 gene (Zweigerdt et al., 1997). Two YACs carrying
the nlacZ reporter gene inserted into the MRF4 open reading
frame (KpnI site) plus approximately 500 kb downstream
sequence and 85 or 36 kb upstream sequence, respectively,
showed comparable myotomal expression in somites ofE9.5/E10.5 embryos (Fig. 1A), which appeared very similar
to the endogenous MRF4 gene. However, details of the
expression patterns could not be assessed due to the chime-
ric nature of the embryos. Removal of most sequence
downstream of Myf5 had no appreciable effect on MRF4-
reporter activity (data not shown), indicating that expression
was essentially driven by sequences located within 36 kb
5V-upstream and approximately 15 kb 3V-downstream of the
gene. To further delineate important control regions, we
constructed a series of MRF4 transgenes in plasmids con-
taining promoter fragments and 3V gene flanking sequences
of various lengths (Fig. 1B). The individual constructs
exhibited fairly consistent expression patterns in somites
of multiple transient transgenic embryos and stable mouse
lines (see Table 1), although ectopic expression domains and
variations in signal intensity were observed occasionally.
Transgene MRF4-I, encompassing 20.1 kb upstream and
15.3 kb downstream sequence from the MRF4 gene (coor-
Table 1
Summary of transgenic embryos expressing h-galactosidase in somites
Transgene Transient Line Somitic expression Ectopica
E9.5 E10.5 E11.5 E12.5
MRF4-I 12 1 2(2) 5(5) 6(6) 3(3) 6(13)
MRF4-II 7 1 2(2) 3(3) 3(3) 3(3) 1(8)
MRF4-III 7 1 2(2) 4(4) 3(3) 2(2) 2(8)
MRF4-IV 12 1 1(1) 5(5) 8(8) 2(2) 1(13)
MRF4-V 18 4 0(4) 0(10) 0(10) 0(10) 1(22)
MRF4-VI 16 2 3(3) 8(8) 8(9) 3(4) 5(18)
MRF4-VII 4 3 4(4) 4(4) 5(5) 3(3) 2(7)
MRF4-VIII 8 1 0(4) 0(4) 0(1) 0(1) 1(9)
MRF4-IX 9 4 6(6) 7(7) 6(7) 4(5) 4(13)
MRF4-X 7 2 3(3) 5(5) 4(4) 3(3) 2(9)
Embryos that were positively genotyped for the lacZ transgene and
expressed h-galactosidase in somites are listed, except for MRF4-V and
MRF4-VIII, which failed to express the reporter but contained the
transgene. Numbers in parenthesis refer to total number of examined
transient embryos and lines at different stages.
a Variable ectopic expression was mostly observed in head mesenchyme
and rarely in neural tube and branchial arches at various developmental
stages.
Fig. 2. Time course of embryos containing the reporter construct MRF4-I
stained for h-galactosidase. Expression starts at E9.0 (19 somites) in the
dorsal part of cranial somites (marked by arrowhead in the inset of panel A)
and proceeds during subsequent development rostrocaudally along the body
axis as well as in dorsoventral direction within somites (A–C). By E11.5
expression is also seen in the ventral part of thoracic somites (arrowhead in
C). Transgene expression is already markedly down-regulated in cervical
and thoracic somites at E12.5 (D). Ectopic expression is occasionally
observed in head mesenchyme. Transverse sections of E9.5 (E) and E10.5
(F) embryos (levels are indicated by lines in panels A and B, respectively)
illustrate expression in the central myotome of young somites sparing the
most dorsal (epaxial) region demarcated by arrows (E). In more mature
somites, myotomal expression extends further dorsally (F).
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displayed the dynamic expression pattern in somites of
embryos between E9.0 and E12.5 (Fig. 2), very similar to
the one that has been described previously for the endoge-
nous gene (Bober et al., 1991; Hinterberger et al., 1991;
Summerbell et al., 2002) and for large BAC transgenes
(Carvajal et al., 2001). MRF4-I expression was first initiated
in the embryo at the 19 somite stage (E9) within the dorsal
myotomal half of the most rostral somites but not in the
early epaxial domain that is characteristic for Myf5 (Figs.
2A and E). With further development, expression rapidly
proceeded into more caudal somites (Figs. 2B–D) and also
expanded dorsally (Fig. 2F) and ventrally within individual
somites reaching the ventral myotome in thoracic somites
by E11.5 (Fig. 2C). At E12.5, expression was down-regu-
lated in rostrocaudal direction reflecting the transient wave
of embryonic MRF4 expression in somites (Fig. 2D).
Significantly, the early hypaxial domain of MRF4 expres-
sion in thoracic somites of E9.5–E10.5 embryos that was
identified by in situ hybridization (Summerbell et al., 2002)
and with a BAC transgene (Carvajal et al., 2001) was not
detected with MRF4-I (Figs. 2B and E) or with any other
transgene used in this study. This supports the notion that
early hypaxial expression of MRF4 depends on a far
upstream regulatory element located on the 140 to
88.2 kb sequence interval. It is also noteworthy that
MRF4-I was not activated in branchial arches and the
epaxial dermomyotomal lip of most transgenic embryos,
although the intergenic enhancers driving Myf5 expression
in branchial arches and the early epaxial domain were
present in the construct, suggesting that insulation of the
MRF4 promoter from the branchial arch and early epaxial
enhancers was maintained even in the context of the
relatively small transgene.We next analyzed successively shorter 5V-upstream
sequences that were generated by digestion with appropriate
restriction enzymes. The transgenes MRF4-II and MRF4-III
containing 14 and 11.4 kb sequence upstream of the MRF4
gene, respectively, were robustly expressed in somites of
E10.5 embryos comparable to the pattern obtained with
MRF4-I (Figs. 3A and B). Both constructs were also
expressed in somites at earlier developmental stages, always
limited to the myotome sparing the epaxial dermomyotomal
lip and the extreme epaxial myotomal cells immediately
adjacent to it (data not shown). However, the ventral
extension of the expression domain in thoracic somites
appeared somewhat variable with these constructs, which
may either merely reflect slightly different developmental
stages of the examined embryos or real variability in the
ventral domain when the larger genomic context of the
transgene is not maintained (compare Figs. 3A and B).
MRF4-III was also expressed during foetal stages of devel-
opment (E14.5–E17.5) in skeletal muscles of the trunk and
limbs, in the neck region, and in the tongue, supporting
previous results that sequence relatively near to the MRF4
Fig. 4. Transverse and sagittal sections of E11.5 embryo carrying the
transgene MRF4-III. The plane of section is indicated by the thick line and
different levels along the body axis are shown by arrows. Note that
expression of the transgene is correctly limited to the myotome and extends
from the epaxial (dorsal) to the hypaxial (ventral) domain at interlimb level.
The sagittal section (at hindlimb level) illustrates that the transgene is
particularly strong in the central part of the myotome where nuclei tend to
accumulate. Some nuclear leakage reveals the longitudinal orientation of
spindle-shaped myocytes.
Fig. 3. Expression patterns of 5V- and 3V-truncated MRF4 transgenes in
E10.5 embryos. The somitic expression patterns generated by constructs
MRF4-II, MRF4-III, and MRF4-IV are similar to each other except for
some variability in ventral myotomes of thoracic somites (A–C). In
contrast, MRF4-V containing the 3-kb promoter fragment only supports
very faint expression in cervical somites (D).
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gene activation (data not shown; Patapoutian et al., 1993;
Pin et al., 1997). In construct MRF4-IV, the sequence
downstream of MRF4 including the Myf5 gene was trun-
cated approximately 3.9 kb downstream of the MRF4 gene
to evaluate the potential influence of this region. Like the
previous constructs, this transgene was expressed in all
myotomes of transgenic embryos, suggesting that the down-
stream sequence harboring several enhancers that have been
shown to regulate Myf5 transcription were not necessary for
the somitic pattern of the MRF4 promoter (Fig. 3C). In
contrast, MRF4-V in which the 5V-upstream sequence was
further shortened to 3 kb failed to mediate substantial
expression in embryos (Fig. 3D). This 3-kb promoter
fragment was, however, sufficient to drive the reporter gene
in conjunction with the 58 or 48 kb enhancer (see
below) consistent with previous results that located the
minimal MRF4 promoter in myogenic cell lines within this
region (Black et al., 1995; Naidu et al., 1995). The precise
location of transgene expression within somites was deter-
mined on serial transverse sections of the MRF4-III con-
taining transgenic mouse line. As demonstrated for an E11.5
embryo in Fig. 4, expression was appropriately confined to
the myotome including the dorsal, medial, and ventral
domains in mature thoracic somites. A sagittal section
showed the strongest expression in the medial part of the
myotome, presumably in differentiated myocytes (Fig. 4).
Somitic expression between E9.5 and E12.5 was also
obtained with transgene MRF4-VI that contained a 7.5-kbpromoter fragment driving the reporter gene but lacked any
MRF4 sequences downstream of the KpnI site carrying the
lacZ gene insertion (Figs. 5A–E). This construct appeared
weaker expressed at the early stage (E9.5; Fig. 5A) but
generated the appropriate spatial pattern during somite
development, suggesting that the +3.9 kb sequence includ-
ing the MRF4 gene body was not required to reproduce
embryonic expression in somites. To ascertain that the yeast
Ura gene including its promoter (present in all of the
transgenes as a remnant of YAC selection) did not seriously
affect the expression pattern, the Ura selection cassette was
completely removed from constructs MRF4-IV, MRF4-VI,
and MRF4-X without resulting in any appreciable changes
of the embryonic expression in comparison to the parental
transgene constructs (data not shown). Taken together, these
results indicate that the 7.5-kb MRF4 promoter fragment is
sufficient to direct transient expression in the myotome of
all somites with essential regulatory elements located be-
tween 7.5 and 3 kb upstream of the gene. Although
cooperation of these control elements with the MRF4
promoter (3 kb region) or even with sequences within
the gene (because MRF4-VI expression is weak at E9.5)
may be part of the regulation, known enhancers situated
downstream of MRF4 are apparently not required to drive
the early wave of promoter activity in somites.
Fig. 5. Expression profiles of MRF4 transgenes with various deletions of 5V-upstream sequences during mouse embryogenesis. MRF4-VI containing the 7.5-kb
promoter fragment recapitulates the spatiotemporal pattern of MRF4 expression in somites between E9.5 and E12.5, although expression at E9.5 appears
consistently weak (A–D). Transverse section through thoracic somite of an E11.5 embryo confirms expression in the myotome (E). MRF4-VII carries an
internal deletion from 5.6 to 3 kb within the 7.5-kb MRF4 promoter fragment and generates the appropriate h-galactosidase staining pattern in myotomes of
all somites (F–H), whereas construct MRF4-VIII (5.6 kb promoter fragment) does not support somitic expression at any time of embryonic development
(shown for E10.5 in panel I). The transgene MRF4-IX (3 kb minimal promoter linked to 7.5/6.5 kb sequence) is weakly expressed in cervical, lumbar, and
tail somites but shows no appreciable activity in the interlimb region (J–M). Transverse section of an E11.5 embryo anterior to the forelimb illustrates that
MRF4-IX is also expressed in the myotome (N). MRF4-X (3 kb minimal promoter linked to 6.6/5.6 kb sequence) promotes robust myotomal expression in
all somites along the body axis during the correct developmental time frame (O–R). Note the relatively weak activation of most transgenes in the ventral
myotome of thoracic somites.
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To further dissect the 4.5-kb sequence (7.5/3.5 kb)
containing the putative myotomal MRF4 enhancer, various
deletions were introduced into the 7.5-kb promoter frag-
ment. In construct, MRF4-VII sequence from 7.5 to 5.6
kb was directly linked to the 3-kb MRF4 promoter frag-
ment, thereby deleting 2.6 kb sequence between 5.6 and
3 kb while the entire promoter sequence up to 5.6 kb
was employed in transgene MFR4-VIII (see Fig. 1B).
Significantly, expression of the MRF4-VII transgene started
in cranial somites around E9.0 and expanded into morecaudal somites at E10.5 and E11.5 (Figs. 5F–H). In
contrast, embryos harboring MRF4-VIII essentially failed
to express the transgene in myotomes (Fig. 5I), indicating
that important control elements lie within the 7.5 to 5.6
kb sequence interval. This region was therefore further
subdivided into approximately two halves and both frag-
ments were separately placed in front of the 3-kb promoter
fragment (Fig. 1B). MRF4-IX contained the distal (7.5/
6.5 kb) and MRF4-X the proximal half (6.6/5.6 kb) of
the segment with some overlap in the middle. In contrast to
MRF4-X that was expressed in all somites along the
anteroposterior axis in the appropriate time frame (Figs.
5O–R), MRF4-IX was weakly transcribed only in rostral
and tail somites but not in somites between fore- and
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appeared to be in the epaxial part of the myotome lacking
most of the typical ventral domain in thoracic somites at
E10.5 and E11.5. This observation suggests that additional
elements including those located distantly upstream are
required to collaborate with the enhancer for this aspect of
the expression pattern. Interestingly, at 6.5/6.2 kb within
the 1-kb element employed in MRF4-X, we detected a 264-
bp sequence that was significantly homologous to the
corresponding region of the human MRF4 gene locus
(Fig. 6), while adjacent sequences were highly diverged in
both species. This observation suggests that the 264 con-
served nucleotides may represent the core of this regulatory
region. Computer-based analysis predicted multiple poten-
tial binding sites for transcription factors within this se-
quence, including an E-box consensus sequence none of
which, however, has been tested functionally. Collectively,
these data indicate that a 1-kb fragment, located approxi-
mately 6.5 kb upstream of the MRF4 gene, in conjunction
with the 3-kb promoter fragment, is capable of activating the
MRF4 gene in all somites along the body axis, while theFig. 6. A block of 264 nucleotides at 6.5 kb upstream of the mouse MRF4 gene
Sequence alignment was performed by the Clustal method. Identical nucleotide res
sequence. Nucleotide gaps are marked by dashes.adjacent upstream sequence in the same promoter context
supports only a subset of the pattern.
The MRF4 promoter responds to the strong 48/58 kb
Myf5 enhancer when juxtaposed
We and others had shown previously that a strong
enhancer situated between 58 and 48 kb upstream of
the Myf5 gene directs expression of this myogenic tran-
scription factor to the limb buds and hypoglossal cord, to
sites of myogenesis in the somite, and to specific regions in
the central nervous system in mouse embryos (Buchberger
et al., 2003; Hadchouel et al., 2003; Zweigerdt et al., 1997).
Based on its expression profile, the MRF4 promoter, which
lies closer to the enhancer than the Myf5 gene, appears not
to be regulated by this enhancer. This raises the question of
how this promoter selectivity may be established. We
wanted to know whether properties inherent to the MRF4
promoter itself or the promoter proximal myotomal control
region might prevent regulatory interactions with the en-
hancer. We therefore placed the 2-kb core element (57.7/is highly conserved in the corresponding region of the human MRF4 locus.
idues are indicated by dots and different nucleotides are boxed in the human
Fig. 7. Effect of the core enhancer from the 58/48 kb region on MRF4 transgene expression during embryonic development. The 2-kb enhancer containing
the homology elements H1 and H2 described previously (Buchberger et al., 2003) was linked to the 3-kb MRF4 promoter fragment, which by itself fails to
direct transcription in embryos, or to the 11.4-kb promoter fragment driving the MRF4-nlacZ reporter gene (constructs shown schematically). Panels A–D
show the expression of the 3-kb promoter plus enhancer in somites and limbs (indicated by arrowheads and enlarged in D) at E10.5 (A), E11.5 (B), and E12.5
(C, D). Panels E and F show E12.5 embryos carrying the longer transgene, which also exhibits ectopic expression in limb buds. Thus, in both constructs, the
enhancer dominantly generates the pattern typical for Myf5 rather than for MRF4.
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elements H1 and H2, directly in front of the MRF4 minimal
promoter (3 kb fragment) or in front of the 11.4-kb MRF4
promoter fragment that also contains the regulatory region
for myotomal expression (Fig. 7). Transgenic embryos
generated with both constructs displayed expression in
somites and limbs recapitulating the expression pattern of
the Myf5 gene rather than that of MRF4. This observation
indicates that the MRF4 promoter is in principle responsive
to the upstream Myf5 enhancer when juxtaposed and the
MRF4 control region (11.4 kb fragment) is unable to
prevent this response. The result excludes the possibility of
a selective promoter–enhancer interaction to achieve en-
hancer specificity and suggests that other elements than
those involved in regulating the MRF4 promoter in the
myotome operate in insulating it from influences by the far
upstream Myf5 enhancer.Discussion
The elements controlling the early phase of MRF4
expression in the mouse embryo have not been defined in
detail; however, a mouse BAC MRF4 transgene containing
59 kb sequence upstream of the Myf5 gene displayed
somitic expression along the entire body axis (Carvajal et
al., 2001), while a 8.5-kb promoter fragment of the MRF4
gene mediated early expression in the central myotome of
thoracic but not rostral and caudal somites (Pin et al., 1997).Expression during the second phase of MRF4 gene activity
in foetal trunk and limb muscles was achieved with a 6.5-kb
fragment of the mouse MRF4 promoter, but this sequence
did not support early expression in somites (Patapoutian et
al., 1993). However, within this sequence, enhancer activity
was shown in muscle cell culture (Kerkvliet and Hinter-
berger, 1997) and in fast muscle fibers of adult mice (Pin
and Konieczny, 2002). Our analysis of the MRF4 gene in
transgenic animals provides evidence that a regulatory
element situated relatively close to the promoter is necessary
and in the context of the 3 to +3.9 kb MRF4 gene also
sufficient to drive most aspects of embryonic MRF4 ex-
pression in the myotome of all somites. A major difference
of the patterns obtained with our transgenes compared to the
endogenous MRF4 gene (Bober et al., 1991; Hinterberger et
al., 1991; Summerbell et al., 2002) and a BAC transgene
containing 140 kb sequence upstream of the Myf5 tran-
scriptional start site (Carvajal et al., 2001) was, however, the
lack of early expression in the hypaxial myotome and the
noticeable variability in the ventral myotome of thoracic
somites at later stages (E10.5–E11.5). This observation
argues that most likely additional control elements are
required to faithfully recapitulate the complete and stable
dorsoventral MRF4 pattern in somites. Indeed, a distal
element further than 88 kb upstream of Myf5 has already
been shown to be responsible for early MRF4 expression in
the hypaxial dermomyotome before or simultaneously with
Myf5 (Carvajal et al., 2001; Summerbell et al., 2002).
Whether the same distal element or also other regions
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of more mature somites remains to be seen.
The analysis of various deletions within the 7.5-kb MRF4
promoter points to the importance of the 1-kb sequence
between 6.6 and 5.6 kb upstream of MRF4 for establish-
ing the first wave of MRF4 expression in the myotome. This
sequence in the context of the 3-kb MRF4 promoter, and the
gene itself (MRF4-X) mediates a spatiotemporal pattern that
is very reminiscent of the endogenous MRF4 gene (except
for the hypaxial domain described above). The corre-
sponding transgene lacking this 1-kb sequence (MRF4-V)
is essentially not expressed in the mouse embryo, although it
contains the minimal promoter that has been demonstrated to
be active in cultured myogenic cells (Naidu, Black) as well
as with the 58/48 kb Myf5 enhancer in vivo, as shown
here. Clearly, the 3-kb MRF4 promoter sequence alone is not
sufficient to direct expression in somites. As we have not
examined the 6.6/5.6 kb element with heterologous
promoters, we do not know if it behaves like a classical
enhancer or specifically collaborates with the MRF4 pro-
moter. The homologous genomic context in our transgenes
was intentionally maintained as much as possible because it
has been shown recently that the early epaxial Myf5 enhanc-
er regulates heterologous promoters quite differently from
the corresponding endogenous Myf5 promoter (Teboul et al.,
2003).
Previous work by Patapoutian et al. (1993) used 6.5 kb
sequence upstream of MRF4 to drive expression of a lacZ
transgene in mice but expression was not observed during
early somitic development in three transgenic mouse lines.
This sequence corresponds to the region studied here and
encompasses the regulatory element at 6.6/5.6 kb,
provided that the BamHI/SalI fragment used by Patapoutian
et al. (1993) was actually 7.2 kb in length as predicted by
the genomic sequence and not 6.5 kb as stated by the
authors. In contrast to the previous study, most of our
constructs contained the +3.9 kb sequence, including the
complete MRF4 gene, which may exert a stabilizing effect
for the efficient and consistent expression in somites. This
additional sequence, however, is not absolutely required for
the embryonic pattern in somites, as the transgene MRF4-VI
that is most similar to Patapoutian’s construct and lacks
most of the MRF4 gene body and downstream sequences
was expressed in the embryo. It should be mentioned that
we also obtained two out of four MRF4-VI transgenic lines
that failed to express h-galactosidase in somites (data not
shown), suggesting that expression might have been missed
by Patapoutian et al. (1993) for statistical reasons. The
regulatory region of the mouse MRF4 gene also completely
overlaps with the analyzed promoter region of the rat that,
however, was only expressed in thoracic somites (Pin et al.,
1997). None of our mouse transgenes elicited a partial
expression pattern limited to thoracic somites but they either
were not expressed in all somites (MRF4-VIII) or were
restricted to cervical and tail somites (MRF4-IX), exhibiting
the complementary pattern to the rat transgene. Neverthe-less, at least 8 kb sequence upstream of both MRF4 genes is
highly conserved with approximately 85% sequence identity
in both species. While we are confident that the consistent
expression patterns observed with various constructs in
relatively large numbers of transient and stable transgenic
animals truly reflect an important control region, we have no
good explanation for the disparate observations in the two
rodents other than that subtle variations in sequence may
cause the difference. Interestingly, 250 nucleotides located
within the critical 6.6 to 5.6 kb mouse regulatory region
are also highly homologous to the human MRF4 gene
providing circumstantial evidence that this element indeed
serves a conserved regulatory function. In conclusion, we
propose that in the mouse embryo the early phase of MRF4
expression in somites is at least in part controlled by a
regulatory element that is located around 6.5 kb upstream
of the MRF4 gene. This element presumably collaborates
with additional genomic regions, some located distantly
upstream (140/88.2 kb) (Carvajal et al., 2001), to
ascertain consistent expression in the most ventral part of
the hypaxial myotome. In agreement with previous studies,
we find that elements contained within the MRF4 promoter
proximal region also direct expression in most, if not all,
skeletal muscles between E14.5 and E17.5 (data not shown).
Thus, different from Myf5 gene regulation, most aspects of
the MRF4 expression profile seem to be controlled by
sequences relatively close to the promoter.
The complexity of multiple modular regulatory elements in
the Myf5/MRF4 locus requires mechanisms to specify
promoter responsiveness
Multiple regulatory elements are dispersed throughout
the MRF4/Myf5 locus, some of them at large distances from
the MRF4 and Myf5 promoters. In addition, the protein
tyrosine phosphatase gene, Ptprq, overlaps with the MRF4/
Myf5 locus but is not expressed in skeletal muscle (Wright
et al., 1998). Obviously, this gene is regulated differently.
The interdigitated arrangement of modular control sequen-
ces within the locus raises the question whether and if so to
what extent the regulatory elements affect the promoters of
both myogenic factor genes. Since MRF4 is not expressed
in the early epaxial dermomyotome and in branchial arches,
these enhancers situated between both genes probably only
regulate Myf5 expression and do not control the MRF4
promoter. Some of the transgenes (MRF4-I to III) examined
here would support this view. A mechanism underlying the
selective promoter interactions in this case may follow the
model of promoter–enhancer competition as shown for the
imprinted Igf2/H19 locus, in which a chromatin insulator
regulates the interaction of the enhancer with the promoter
(Webber et al., 1998).
The58/48 kb regulatory region has been demonstrated
to be important for Myf5 expression in limb buds and certain
aspects in somites (Buchberger et al., 2003; Hadchouel et al.,
2003) but apparently does not activate theMRF4 promoter, at
M. Fomin et al. / Developmental Biology 272 (2004) 498–509508least not in limb buds. This is despite the fact that the
enhancer lies closer to the MRF4 than to the Myf5 promoter
excluding a model of linear gene array like in the HoxD
cluster where the enhancer preferentially interacts with the
nearest promoter first (Kmita et al., 2002; Monge et al., 2003;
Spitz et al., 2003). We tested the alternative possibility of
target specificity brought about either by the MRF4 promoter
itself or the nearby regulatory element. Our data clearly
indicate that the 58/48 kb enhancer can interact with the
MRF4 promoter and the promoter proximal element driving
myotomal expression of MRF4 is unable to prevent this
interaction. Thus, a mechanism of selective promoter–en-
hancer interaction based on target specificity seems very
unlikely. Since a BAC clone containing 59 kb upstream of
Myf5 drives the correct spatiotemporal expression pattern of
the MRF4 transgene (Carvajal et al., 2001), it is reasonable to
assume that an element located between the 58/48 kb
enhancer and 11.4 kb from the MRF4 gene is essential for
shielding the promoter.Acknowledgments
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